Page 85 - Read Online

Page 12 of 13 Canepa et al. Vessel Plus 2022;6:30 https://dx.doi.org/10.20517/2574-1209.2021.106

2021;9:169-78. DOI PubMed
47. d’Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed
valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J 2016;37:3515-22. DOI PubMed PMC
48. Lüscher TF. Aortic stenosis: expanding treatment options. Eur Heart J 2016;37:3483-5. DOI PubMed
49. Mack MJ, Leon MB, Thourani VH, et al; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-
expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705. DOI PubMed
50. Griffin JM, Maurer MS. Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do? Eur J Heart Fail
2020;22:1863-5. DOI PubMed
51. Cecchi F, Olivotto I, Betocchi S, et al. The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. Am Heart J
2005;150:947-54. DOI PubMed
52. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in
the United States. Am J Cardiol 2016;117:1651-4. DOI PubMed
53. Canepa M, Fumagalli C, Tini C, et al. Temporal trend in age at diagnosis of hypertrophic cardiomyopathy: an analysis of the share
registry. Circulation 2019;140:A16286. DOI
54. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol
2017;70:466-77. DOI PubMed
55. Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with
disopyramide. Circulation 2012;125:1821-4. DOI PubMed
56. Mookadam F, Haley JH, Olson LJ, Cikes M, Mookadam M. Dynamic left ventricular outflow tract obstruction in senile cardiac
amyloidosis. Eur J Echocardiogr 2006;7:465-8. DOI PubMed
57. Maron BJ, Casey SA, Haas TS, Kitner CL, Garberich RF, Lesser JR. Hypertrophic cardiomyopathy with longevity to 90 years or
older. Am J Cardiol 2012;109:1341-7. DOI PubMed
58. Robins LN, Marcus SC. The diagnostic screening procedure writer: a tool to develop individualized screening procedures. Med Care
1987;25:S106-22. DOI PubMed
59. Alexander KM, Witteles RM. Management of cardiac amyloidosis: do’s and don’ts. Can J Cardiol 2020;36:444-6. DOI PubMed
60. Hanna M, Ruberg FL, Maurer MS, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected
amyloidosis: JACC review topic of the week. J Am Coll Cardiol 2020;75:2851-62. DOI PubMed
61. Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in
evolution. JACC Cardiovasc Imaging 2021;14:1221-31. DOI PubMed PMC
62. Geller HI, Singh A, Mirto TM, et al. Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis. Mayo Clin Proc
2017;92:1800-5. DOI PubMed
63. Abildgaard N, Rojek AM, Møller HE, et al. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.
Amyloid 2020;27:59-66. DOI PubMed
64. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. DOI PubMed
65. Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin
(ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging 2017;18:1344-
50. DOI PubMed
66. Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting
survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880-9. DOI PubMed
67. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-
related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70. DOI PubMed
68. Cappelli F, Gallini C, Costanzo EN, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with
TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol 2018;254:346-50. DOI PubMed
69. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for
multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol
2019;26:2065-123. DOI PubMed
70. Masri A, Bukhari S, Ahmad S, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of
transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249. DOI PubMed PMC
71. Poterucha TJ, Elias P, Ruberg FL, et al. False positive 99mTc-pyrophosphate scanning leading to inappropriate tafamidis prescriptions.
JACC Cardiovasc Imaging 2021;14:2042-4. DOI PubMed
72. Hussain M, Collier P, Jaber W. Value of SPECT imaging in patients with TTR-amyloid: ratios are not enough. J Nucl Cardiol
2021;28:747-9. DOI PubMed
73. Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin
cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:1314-21. DOI PubMed
74. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy-a heart failure Society of America Practice
Guideline. J Card Fail 2018;24:281-302. DOI PubMed
75. Adams D, Suhr OB, Hund E, et al; European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis,
management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29 Suppl 1:S14-26. DOI